Knight Therapeutics Inc. stock has seen a modest uptick recently amid significant regulatory advancements.
This week, Knight Therapeutics Inc. (GUD.TO) experienced a slight increase in share price, closing at C$10.04, marking a 0.31% gain on the day. However, over the past week, the stock has dipped by approximately 0.92%. Despite these fluctuations, the year-to-date performance remains strong, with an impressive 63.62% increase.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$946.95M
P/E
64.3x
52W high
$10.17
52W low
$5.66
1W change
-0.92%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 15.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+15.7% Upside
Current Price
C$9.67
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
32.9%
Annualized
90-Day Vol
32.5%
Annualized
Trend (90d)
+23.7%
Annualized drift
90d Mean
C$10.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.95 | C$8.88 – C$11.14 |
| 60 trading days | C$10.23 | C$8.72 – C$12.01 |
| 90 trading days | C$10.52 | C$8.65 – C$12.81 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the recent regulatory approvals and their potential impact on future growth, while also being mindful of the stock's recent performance trends.
Knight Therapeutics Inc. stock closed at C$10.04, reflecting a year-to-date gain of 63.62%.
The stock's 52-week range of C$5.66 to C$10.17 showcases its significant growth potential, but recent performance indicates volatility.
Bull case
The recent approval of TAVALISSE® in Colombia and the supplemental submission for MINJUVI® in Brazil are positive developments for Knight Therapeutics. These approvals could lead to increased revenue from these products, enhancing the company’s growth prospects.
Bear case
Despite the encouraging regulatory news, the stock has shown slight declines over the past week and month. This trend may raise concerns about its short-term stability and market performance, especially in the context of broader market conditions.
Recent Price Action
Advertisement
Knight Therapeutics Inc. has closed at C$10.04, reflecting a modest gain of 0.31% on Thursday. However, the stock has faced a decline of approximately 0.92% over the past week and a 1.73% drop in the last month. Despite these fluctuations, the year-to-date performance remains robust at +63.62%, indicating strong investor interest.
Company News
This week, Knight Therapeutics announced the regulatory approval of TAVALISSE® in Colombia, a significant step that may enhance its market presence in Latin America. Additionally, the company disclosed a supplemental regulatory submission for MINJUVI® (tafasitamab) in Brazil, which could further boost its product offerings in the region. These developments are expected to positively impact the company's growth trajectory.
Technical Picture
From a technical standpoint, Knight Therapeutics is currently trading above its 50-day moving average of C$9.66 by approximately 3.9% and well above its 200-day moving average of C$7.57, indicating long-term strength. The stock has a beta of 0.05, suggesting low volatility compared to the overall market. The current price is 97% of its 52-week range, which spans from C$5.66 to C$10.17. The recent trading volume of 488,430 shares is significantly higher than the 20-day average of 89,162 shares, indicating increased investor interest.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
